Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio EssenceBIOE 31 EBITDA Margin % is 43.11% as of Mar. 2026. GuruFocus rates BIOE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Bio Essence ranks better than 97.5% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bio Essence's EBITDA for the
three
months ended in Mar. 2026 was $0.22 Mil. Bio Essence's Revenue for the
three
months ended in Mar. 2026 was $0.50 Mil. Therefore, Bio Essence's EBITDA margin for the quarter that ended in Mar. 2026 was 43.11%.
Bio Essence (OTCPK:BIOE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bio Essence EBITDA Margin % Related Terms
Bio Essence EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bio Essence's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIOE vs BFRI, APUS, CABR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bio Essence's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Essence EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bio Essence's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bio Essence's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Essence (BIOE) has a EBITDA Margin % of 43.11% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bio Essence and its competitors. According to the industry distribution chart, Bio Essence ranks #24 out of 961 companies in the Drug Manufacturers industry, placing it in the top 2.5%.
Is Bio Essence's EBITDA Margin % too high?
Bio Essence's current EBITDA Margin % is 43.11%. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Bio Essence's value of 43.11% is 245.2% above this industry median. Based on the distribution chart, Bio Essence ranks #24 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bio Essence has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Bio Essence's EBITDA Margin % compare to BFRI and APUS?
According to the Drug Manufacturers industry distribution chart, Bio Essence ranks #24 out of 961 companies for EBITDA Margin %. This places Bio Essence in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.49. Bio Essence's value of 43.11% is 245.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Essence's current EBITDA Margin % of 43.11% is 245.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bio Essence and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Essence's current EBITDA Margin % is 43.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Essence stock overvalued right now?
Bio Essence (BIOE) has a current EBITDA Margin % of 43.11%. The current EBITDA Margin % is 43.11% and 245.2% above the Drug Manufacturers industry median of 12.49. Bio Essence's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bio Essence (BIOE), the current EBITDA Margin % is 43.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Essence Corp is an herbal health, diet, and nutrition company. The Company's mission is to provide herbal health, diet, and vitamin nutritional supplements. The primary focus of BEP was producing products for BEH and McBE, along with providing original equipment manufacturing and private label services to other companies. BEH targeted and developed traditional Chinese medicines (TCM) in the form of single herbs, granules, pills, and tablets. It also offered specially formulated dietary supplements and medical food. The Company operates in one business and industry segment: the manufacture / OEM and sale of health supplement products. The group's products are RED Yeast Rice Plus, Regenva, MediDrink, and Nufargo.
31GF Score
Get the complete analysis for BIOE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOE has been successfully added to your 
